Compositions and methods for increasing stress response and improving health and slowing the aging process in a user. A composition includes one or more of a first group consisting of milk thistle, ashwagandha, green tea, bacopa monnieri, and turmeric. The composition includes one or more of a second group consisting of acetyl-L-carnitine, quercetin, lipoic acid, coenzyme Q10, cysteine, and grape. The composition includes one or more of a third group consisting of capsaicin, wasabi, olive leaf extract, nicotinic acid, and copper gluconate.

This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.

This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.

The uses of the disclosed copper-cysteamine (Cu-Cy) complex for methods for treating Gram-positive and Gram-negative infections in subjects and for disinfecting a surface are disclosed. In addition, the disclosed Cy-Cy nanoparticles provide Fenton-like reactions in vivo, in vitro and ex vivo.

The uses of the disclosed copper-cysteamine (Cu-Cy) complex for methods for treating Gram-positive and Gram-negative infections in subjects and for disinfecting a surface are disclosed. In addition, the disclosed Cy-Cy nanoparticles provide Fenton-like reactions in vivo, in vitro and ex vivo.

Provided is a method of forming a copper-containing complex, including contacting a sample containing copper with a compound of Formula I:

##STR00001##

wherein R is OH or OCH3. Also provided is a method of inhibiting enzymatic activity of a kinase in a sample, including contacting the sample with a compound of Formula I. Further provided is a method of administering to a subject a pharmaceutical composition including a compound of Formula I optionally complexed with copper. Also provided is a pharmaceutical composition including copper complexed with a compound of Formula I.

Provided is a method of forming a copper-containing complex, including contacting a sample containing copper with a compound of Formula I:

##STR00001##

wherein R is OH or OCH3. Also provided is a method of inhibiting enzymatic activity of a kinase in a sample, including contacting the sample with a compound of Formula I. Further provided is a method of administering to a subject a pharmaceutical composition including a compound of Formula I optionally complexed with copper. Also provided is a pharmaceutical composition including copper complexed with a compound of Formula I.

The present invention provides a method for treating pleuroperitoneal membrane cancers, and comprises: delivering disulfiram or a derivative thereof that is effective in amount in the treatment, into the pleura and/or the peritoneum of a test person that needs to be treated. The present invention also provides a pharmaceutical component comprising the disulfiram or the derivative thereof, and a reagent kit.

The present invention provides a method for treating pleuroperitoneal membrane cancers, and comprises: delivering disulfiram or a derivative thereof that is effective in amount in the treatment, into the pleura and/or the peritoneum of a test person that needs to be treated. The present invention also provides a pharmaceutical component comprising the disulfiram or the derivative thereof, and a reagent kit.

The present invention relates to a microelement organic O-chelate or N-chelate complex compound, for the inhibition of facultative pathogenic bacteria. The present invention further relates to a composition, feed additive or feed comprising the compounds, as well as methods for the preparation thereof, and for the use thereof in animal stock farming.